fda compounding glp-1 warning letters september 2025 Targets and Peptide Compounding, Advertising and 'Research Use Only' Labeling FDA Issues Warning Letters to

You have persistent vomiting or diarrhoea : These symptoms, especially if accompanied by reduced urine output, could lead to dehydration and acute kidney injury, requiring prompt medical attention

Victoria Garfinkle

Studies in diet-induced obese animal models have demonstrated that chronic MC4R agonist treatment produces substantial weight loss accompanied by improved glucose tolerance and insulin sensitivity

For example, a patient with a BMI of 31 may technically meet BMI requirements, but insurance approval could still be denied if required documentation is missing

Timeline depends on your skin type, absorption rate, and daily sun exposure

Maybe some could, eventually